Krystal Biotech, Inc., a burgeoning biotechnology firm committed to the development of genetic medicines for rare diseases, has announced the pursuit of innovative treatments for an array of severe medical conditions. With an emphasis on genetic-based technologies, Krystal Biotech has committed extensive resources to propel groundbreaking initiatives aimed at benefiting patients in the United States. At present, the cutting-edge company is developing beremagene geperpavec (B-VEC) to combat dystrophic epidermolysis bullosa, KB105 for treating patients with deficient autosomal recessive congenital ichthyosis, KB104 for netherton syndrome, and KB407 for those with Cystic Fibrosis. Krystal Biotech is also actively exploring KB408 for Alpha-1 antitrypsin deficiency and KB301 for aesthetic skin conditions. Established in 2016, Krystal Biotech operates out of their Pennsylvania-based headquarters.